Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Genagon Therapeutics

Genagon Therapeutics
2015 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Seed LATEST DEAL TYPE
$235K LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of bio-pharmaceuticals products designed to increase response rates in immuno-oncology. The company's bio-pharmaceuticals products helps to identify novel pathways in immune cells and discovered a new mechanism which cancers use to inhibit the innate immune system, enabling doctors to offer treatment for oncology and inflammatory diseases.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Primary Office
  • Gustaf V Research Institute Building M1
  • Karolinska University Hospital
  • 171 76 Solna
  • Sweden
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Genagon Therapeutics’s full profile, request a free trial.

Genagon Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 26-Jan-2016 $235K 00000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Genagon Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Almi Invest Venture Capital Minority 000 0000 000000 0

Genagon Therapeutics Executive Team (5)

Name Title Board
Seat
Contact
Info
Simon Fredriksson Ph.D Co-Founder & Chief Executive Officer
Gunther Galler Chief Technology Officer
Andries Blokzijl Co-Founder & CSO
Anders Nordström Chairman
Claes Tomas Post Ph.D Ledamot

Genagon Therapeutics Board Members (5)

Name Representing Role Since Contact
Info
Anders Nordström Self Chairman 000 0000
Karin von Wachenfeldt Ph.D Self Board Member 000 0000
Ola Winqvist Ph.D Genagon Therapeutics Board Member 000 0000
Richard Åhlberg Ph.D Genagon Therapeutics Board Member 000 0000
Svein Arild Mathisen Genagon Therapeutics Board Member 000 0000